WARNING!
This is an older article that may not reflect Dr. Mercola’s current view on this topic. Use our search engine to find Dr. Mercola’s latest position on any health topic.
An overview of recent studies finds that there are no clear benefits to using long-acting beta2-agonists (LABAs) for the treatment of asthma in children. Researchers report that there is currently insufficient evidence to suggest that the drugs offer any additional benefit when used in conjunction with conventional preventative medications.